UCB reformulating Parkinson's patch to eliminate crystals

Biopharma company UCB will reformulate its Parkinson's disease and restless leg syndrome drug Neupro before making it available on the U.S. market, per recommendation of the FDA. The regulator's decision answers an NDA supplement submitted by the Belgian drugmaker in June 2009, which proposed new refrigerated storage conditions to alleviate crystallization on the transdermal patches. The FDA agreed that improved storage helped alleviate the problem, but reformulation provided "definitive resolution." Item

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.